The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: The Fujian prospective investigation of cancer (FIESTA) study

Peng, Feng; Hu, Dan; Lin, Xiaoxiao; Chen, Gang; Liang, Binying; Li, Chao; Chen, Yan; Cui, Zhaolei; Zhang, Hejun; Lin, Jixiu; Zheng, Xiongwei; Niu, Wenquan

doi:10.7150/jca.18000

Cited by 33 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several systemic inflammation-based prognostic biomarkers have been identified, such as NLR, PLR, lymphocyte-to-monocyte ratio and C-reactive protein, as potential cancer risk or prognostic factors (31–35). In particular, NLR and PLR are two inflammatory biomarkers that are extensively evaluated in the medical literature, and they were found to be associated with the significant risk of EC, GC, and CRC in our prior studies (13, 15, 16). However, a common problem facing scientific community is to seek optimal cutting points for both biomarkers, which are constrained by some methodological issues, such as statistical power and follow-up interval.…”

Section: Discussionmentioning

confidence: 82%

Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study

Zhang

Lin

et al. 2019

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Objectives: We sought to determine the optimal cutting points for two inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), to assess their prognostic value in patients with postoperative digestive tract cancers overall and by cancer sites, and further to construct an inflammation-related index based on the two biomarkers and assess its predictive performance. Methods: Total 6,865 assessable patients with digestive tract cancers who underwent tumor resection were consecutively enrolled from Fujian Cancer Hospital between January 2000 and December 2010, including 2535/3012/1318 patients with esophageal/gastric/colorectal cancer. The latest follow-up (median: 44.9 months) ended in December 2015. Optimal cutting points were determined using survival tree analysis overall and by cancer sites. Results: Among all study patients, the optimal cutting points were 2.07 and 168.50 to define high and low NLR and PLR, respectively. High NLR (hazard ratio [HR]: 1.48, 95% confidence interval [CI]: 1.37–1.61) and high PLR (HR: 1.41, 95% CI: 1.29–1.53) were associated with a significantly increased risk for the mortality of digestive tract cancers as a whole. By cancer sites, effect-size estimates were comparable and statistically significant. Elevation over the selected optimal cutting points for both NLR and PLR was associated with 1.69-fold increased risk of cancer-specific mortality compared to patients with simultaneously low NLR and PLR among all study patients, and this association persisted by cancer sites, especially for gastric cancer. Conclusions: Our findings demonstrate that the preoperative integrated NLR and PLR, as an inflammation-related index, is a significant independent predictor for postoperative mortality in Chinese patients with digestive tract cancers both overall and by cancer sites.

show abstract

Section: Discussionmentioning

confidence: 82%

Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study

Zhang

Lin

et al. 2019

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inflammation is an important feature of the tumor microenvironment and has been associated with poor prognosis for various tumors (20). Hematological inflammatory parameters such as neutrophils, lymphocytes, monocytes, and platelets can reflect the immune status and offer important predictive value for tumor prognosis (21,22). Giorgi et al identified a PLR <232 as a statistical biomarker for improved OS among mRCC patients treated with nivolumab (23).…”

Section: Discussionmentioning

confidence: 99%

Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Kobayashi

Iikura

Hiraide

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-tolymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma. Patients and Methods Study design. We retrospectively reviewed the medical records of all patients with mRCC who were previously treated with VEGFtargeted therapy and who started treatment with nivolumab at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between September 2016 and September 2018. This review identified 53 eligible patients who received nivolumab monotherapy. Patients with known active or suspected autoimmune disease and patients requiring immunosuppressive medications were excluded from participation in this study. Treatment regimen and study drugs. Based on the results from a previous clinical trial (1), patients were given nivolumab every 2 weeks until the end of treatment or follow-up. In Japan, the 2647 This article is freely accessible online.

show abstract

“…Inflammation is an important feature of tumor microenvironment and associated with poor prognosis of various types of tumor . Hematological inflammatory parameters such as neutrophil, lymphocyte, monocytes, and platelets can reflect the immune status and have important predictive value for the prognosis of tumors . Some studies have evaluated the value of some blood cell count indexes, particularly the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and demonstrated these biomarkers have the prognostic role in different tumors include NSCLC .…”

Section: Introductionmentioning

confidence: 99%

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

Liu¹,

Li²,

Zhang³

et al. 2019

Clinical Laboratory Analysis

231

151

View full text Add to dashboard Cite

Background Explore markers to predict the clinical outcomes of checkpoint inhibitors have high unmet needs. The following study investigates whether hematologic parameter such as systemic immune‐inflammation index (SII), neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) is associated with nivolumab efficacy in advanced non‐small‐cell lung cancer (NSCLC). Methods Advanced/metastatic NSCLC patients treated with nivolumab monotherapy for second‐line or further‐line treatment at Jilin Cancer Hospital between March 2016 and July 2018 were enrolled in this retrospective study. The optimal cutoff values of SII, NLR, and PLR for predicting efficacy and prognosis were determined according to receiver operating characteristic (ROC) curve and the areas under the ROC curve. Progression‐free survival (PFS) and overall survival (OS) were calculated and compared using Kaplan‐Meier method and log‐rank test. Prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression (PHR) analyses. Results A total of 44 patients with advanced NSCLC were included; the median age was 60 (range: 43‐74). The optimal cutoff value of SII/NLR/PLR predicted PFS and OS was 603.5, 3.07, and 144. Low SII, NLR, and PLR were associated with longer PFS (HR for SII = 0.34, 95%CI 0.15‐0.76, P = 0.006; HR for NLR = 0.46, 95%CI 0.22‐0.99, P = 0.048; HR for PLR = 0.39, 95%CI 0.17‐0.94, P = 0.025) and OS (HR for SII = 0.16, 95%CI 0.05‐0.51, P = 0.005; HR for NLR = 0.20, 95%CI 0.06‐0.62, P = 0.002; HR for PLR = 0.20, 95%CI 0.06‐0.73, P = 0.008). NLR ≤ 3.07, PLR ≤ 144, SII ≤ 603.5 were independently associated with longer PFS and OS. Conclusion The SII, NLR, and PLR are promising prognostic predictor for patients with metastatic NSCLC patients.

show abstract

The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: The Fujian prospective investigation of cancer (FIESTA) study

Cited by 33 publications

References 39 publications

Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study

Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study

Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

Contact Info

Product

Resources

About